Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 204

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1A
Chunk 204
---
 intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: 

•others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own; 

•we might not have been the first to make the inventions covered by the issued patents or patent application that we own; 

•we might not have been the first to file patent applications covering certain of our inventions; 

•others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; 

•it is possible that our pending patent applications will not lead to issued patents; 

•issued patents that we own may be held invalid or unenforceable, as a result of legal challenges by our competitors; 

•our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; 

•we may not develop additional proprietary technologies that are patentable; and 

•the patents of others may have an adverse effect on our business. 

Should any of these events occur, it could significantly harm our business, results of operations and prospects. 

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. 

Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents